积极学习辅助探索阿尔茨海默病治疗见解
Lincan Fang1, Ruoxue Peng1, Luping Xia1
1Key Laboratory of Functional Molecular Solids Ministry of Education, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui, 241002, P.R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 20, 2025
概括
通过破坏粉样蛋白β (Aβ) 聚合,可抑制阿尔茨海默病 (AD). 计算研究显示POM通过弱相互作用与Aβ结合,稳定复合体并阻碍自我组装.
科学领域:
- 计算化学
- 生物化学
- 材料科学
背景情况:
- 阿尔茨海默病 (AD) 的特征是粉样蛋白-β (Aβ) 聚合.
- 聚氧甲酸盐 (POMs),如[PMo12O40]3-,显示为阿尔茨海默病的治疗调节剂的潜力.
- 了解POMs对Aβ聚合的精确抑制机制对于治疗发展至关重要.
研究的目的:
- 阐明POMs抑制Aβ聚合的分子机制.
- 使用计算方法探索PMo12O403-和Aβ之间的相互作用.
- 确定参与POM介导的Aβ抑制的主要残留物和相互作用类型.
主要方法:
- 一种集成主动学习贝叶斯优化 (BO) 和密度函数理论 (DFT) 的多尺度计算策略.
- 对孤立的氨基酸,POM-氨基酸复合物和POM-系统的低能配置的探索.
- 对控制吸附稳定性的结,库伦比排斥和弱相互作用 (范德瓦尔斯,疏水) 的分析.
主要成果:
- 结合和库伦比排斥是吸附稳定的主要驱动因素.
- [PMo12O40]3-中的氧原子与Aβ的侧链形成多重弱相互作用.
- 这些协同作用的弱相互作用导致强大的结合,稳定复合体,并阻碍Aβ自我组装.
- 在关键的Aβ聚合区域中,POMs优先向疏水氨基酸 (氨酸,氨酸,白氨酸,异氨酸).
结论:
- 多元药物弱相互作用是POM介导的Aβ聚合抑制的关键.
- 该研究确定了Aβ中的特定界面残留物,这些残留物对于POM的治疗向至关重要.
- 这些发现为设计基于POM的阿尔茨海默病治疗提供了分子基础.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
663
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
相关概念视频
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
